The trajectory of companies tied to Viagra's past presents a intricate investment picture . While the initial surge generated substantial returns , generic alternatives have significantly impacted revenue. Investing in associated pharmaceutical firms now requires a careful assessment of intellectual property protection , evolving patient shifts , a